Literature DB >> 17607313

Progress and prospects: RNA-based therapies for treatment of HIV infection.

L Scherer1, J J Rossi, M S Weinberg.   

Abstract

The current treatment regimen for HIV-infected individuals combines two or more drugs targeting different viral proteins such as RT and gag. Resistance to conventional drugs can develop quickly, and typically persists. The prospect of longer, continuous antiretroviral therapy brings with it the need for new antiretroviral drugs and approaches. In this context, gene therapies have the potential to prolong life and quality of life as an additional therapeutic class and may serve as an adjuvant to traditional treatments. This review focuses on RNA-based hematopoietic cell gene therapy for treatment of HIV infection. Recent advances in our understanding of RNA interference (RNAi) make this an especially attractive candidate for anti-HIV gene therapy although ribozyme and RNA decoy/aptamer approaches can be combined with RNAi to make a combinatorial therapy akin to highly active anti-retroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17607313     DOI: 10.1038/sj.gt.3302977

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  36 in total

1.  Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.

Authors:  Jiehua Zhou; C Preston Neff; Xiaoxuan Liu; Jane Zhang; Haitang Li; David D Smith; Piotr Swiderski; Tawfik Aboellail; Yuanyu Huang; Quan Du; Zicai Liang; Ling Peng; Ramesh Akkina; John J Rossi
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 2.  Current progress in the development of RNAi-based therapeutics for HIV-1.

Authors:  J Zhou; J J Rossi
Journal:  Gene Ther       Date:  2011-09-29       Impact factor: 5.250

3.  Permanent silencing of NKG2A expression for cell-based therapeutics.

Authors:  Constança Figueiredo; Axel Seltsam; Rainer Blasczyk
Journal:  J Mol Med (Berl)       Date:  2008-11-11       Impact factor: 4.599

4.  Self-assembling RNA nanorings based on RNAI/II inverse kissing complexes.

Authors:  Wade W Grabow; Paul Zakrevsky; Kirill A Afonin; Arkadiusz Chworos; Bruce A Shapiro; Luc Jaeger
Journal:  Nano Lett       Date:  2011-01-13       Impact factor: 11.189

Review 5.  Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.

Authors:  Jiehua Zhou; John Rossi
Journal:  J Investig Med       Date:  2014-10       Impact factor: 2.895

Review 6.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

7.  Aptamer-targeted cell-specific RNA interference.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Silence       Date:  2010-02-01

8.  Methods for assessing DNA hybridization of peptide nucleic acid-titanium dioxide nanoconjugates.

Authors:  Eric M B Brown; Tatjana Paunesku; AiGuo Wu; K Ted Thurn; Benjamin Haley; Jimmy Clark; Taisa Priester; Gayle E Woloschak
Journal:  Anal Biochem       Date:  2008-08-26       Impact factor: 3.365

9.  T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice.

Authors:  Priti Kumar; Hong-Seok Ban; Sang-Soo Kim; Haoquan Wu; Todd Pearson; Dale L Greiner; Amale Laouar; Jiahong Yao; Viraga Haridas; Katsuyoshi Habiro; Yong-Guang Yang; Ji-Hoon Jeong; Kuen-Yong Lee; Yong-Hee Kim; Sung Wan Kim; Matthias Peipp; Georg H Fey; N Manjunath; Leonard D Shultz; Sang-Kyung Lee; Premlata Shankar
Journal:  Cell       Date:  2008-08-07       Impact factor: 41.582

10.  Effective treatment of respiratory alphaherpesvirus infection using RNA interference.

Authors:  Amy Fulton; Sarah T Peters; Gillian A Perkins; Keith W Jarosinski; Armando Damiani; Margaret Brosnahan; Elizabeth L Buckles; Nikolaus Osterrieder; Gerlinde R Van de Walle
Journal:  PLoS One       Date:  2009-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.